Intellia’s in vivo gene therapy victorious in Phase III HAE trial
Intellia Therapeutics is set to seek US approval of its in vivo CRISPR gene therapy in hereditary angioedema (HAE) after…
Latest News
-
-
Non-animal testing goes mainstream, but success hinges on smart use
As new approach methodologies (NAMs) burst onto the scene amid the wider shift away from animal testing, biotech and pharma…
-
J&J’s Imaavy shows two-year benefit in gMG
Johnson & Johnson’s (J&J’s) Imaavy (nipocalimab-aahu) has shown continued benefit for two years in patients with generalised myasthenia gravis (gMG)…
-
Safety concerns continue to plague Roche’s BTK inhibitor in RMS
Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety concerns continue to cloud…
-
AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data
AstraZeneca plans to seek accelerated approval of Ultomirisin kidney disease after the drug showed benefit after just 34 weeks, meeting…
-
Paradigm Health debuts post-marketing study tool for routine care integration
Clinical trials technology specialist Paradigm Health has introduced a new, late-phase clinical evidence generation platform, which sets out to streamline…
-
AstraZeneca’s COPD drug gains third Phase III win
AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic obstructive pulmonary disorder (COPD). In the MIRANDA…
-
Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory
A Phase III trial of Novo Nordisk’s once-daily tablet has met both co-primary endpoints, reducing vaso-occlusive crises (VOC) and increasing…
-
Storm clinches $56m in Series C for Phase II on lead sarcoma drug
British cancer biotech Storm Therapeutics has secured $56m in a Series C financing round to push its sarcoma therapy, STC-15,…
-
PDS Biotech’s stock up on colorectal cancer trial success
PDS Biotech’s stock has jumped nearly 25% after its tumour-targeting fused antibody drug conjugate (ADC) elicited a 78% response in patients…
